Authors:
Hodsman, AB
Kisiel, M
Adachi, JD
Fraher, LJ
Watson, PH
Citation: Ab. Hodsman et al., Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis, BONE, 27(2), 2000, pp. 311-318
Authors:
Watson, PH
Fraher, LJ
Natale, BV
Kisiel, M
Hendy, GN
Hodsman, AB
Citation: Ph. Watson et al., Nuclear localization of the type 1 parathyroid hormone parathyroid hormone-related peptide receptor in MC3T3-E1 cells: Association with serum-inducedcell proliferation, BONE, 26(3), 2000, pp. 221-225
Authors:
Holdsworth, DW
Thornton, MM
Drost, D
Watson, PH
Fraher, LJ
Hodsman, AB
Citation: Dw. Holdsworth et al., Rapid small-animal dual-energy X-ray absorptiometry using digital radiography, J BONE MIN, 15(12), 2000, pp. 2451-2457
Authors:
Hodsman, AB
Watson, PH
Drost, D
Holdsworth, D
Thornton, M
Hock, J
Bryant, H
Fraher, LJ
Citation: Ab. Hodsman et al., Assessment of maintenance therapy with reduced doses of PTH(1-34) in combination with a raloxifene analogue (LY117018) following anabolic therapy in the ovariectomized rat, BONE, 24(5), 1999, pp. 451-455
Authors:
Hodsman, AB
Drost, D
Fraher, LJ
Holdsworth, D
Thornton, M
Hock, J
Bryant, H
Watson, PH
Citation: Ab. Hodsman et al., The addition of a raloxifene analog (LY117018) allows for reduced PTH(1-34) dosing during reversal of osteopenia in ovariectomized rats, J BONE MIN, 14(5), 1999, pp. 675-679
Citation: Jh. Toogood et al., Serum osteocalcin and procollagen as markers for the risk of osteoporotic fracture in corticosteroid-treated asthmatic adults, J ALLERG CL, 104(4), 1999, pp. 769-774
Authors:
Fraher, LJ
Avram, R
Watson, PH
Hendy, GN
Henderson, JE
Chong, KL
Goltzman, D
Morley, P
Willick, GE
Whitfield, JF
Hodsman, AB
Citation: Lj. Fraher et al., Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans, J CLIN END, 84(8), 1999, pp. 2739-2743